• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NorthStar Appoints Peter Pfreundschuh to Board of Managers

    4/15/24 9:00:00 AM ET
    $FREQ
    $URGN
    $VYGR
    $IMMU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FREQ alert in real time by email

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive.

    "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business development, and operational roles in fast growing biotechnology companies. This will add valuable perspectives as NorthStar continues to focus on growing its business to meet the needs of patients who need better treatment options and will also provide us with well-informed counsel as we drive our growth strategy."

    Mr. Pfreundschuh is currently Chief Financial Officer (CFO) & Head of Investor Relations at Voyager Therapeutics (NASDAQ:VYGR) and has previously served as CFO and other executive capacities at Frequency Therapeutics (NASDAQ:FREQ), UroGen Pharmaceuticals (NASDAQ:URGN), Sucampo Pharmaceuticals (NASDAQ:SCMP), Immunomedics (NASDAQ:IMMU), and Circulite Inc. Prior to working in the biotech industry, Mr. Pfreundschuh also held progressively senior roles across Finance, Commercial Operations, and Business Development within the pharmaceutical industry at Johnson & Johnson and AstraZeneca. He started his career as an auditor at Ernst & Young, LLP. Pete graduated from Rutgers University School of Business with a Bachelor of Science in Accounting degree and later received an MBA from Rider University. Pete is a Certified Public Accountant in the State of New Jersey. His extensive experience in start-up and early-stage commercial pharmaceutical companies will provide a strong complement to the expertise and personal backgrounds of other NorthStar Board Members.

    In late 2023, NorthStar announced it would focus its business on delivering high-quality medical radioisotopes to the market and building out its patient dose contract development and manufacturing organization (CDMO). The intent of this focus is both to accelerate growth and to make a more immediate measurable impact on the lives of patients with cancer and other serious illnesses.

    "2024 and the next few years will be critical for NorthStar," said Frank Scholz, NorthStar President and Chief Executive Officer. "We're on the cusp of a global paradigm shift in the development and commercialization of effective new radiodiagnostics and radiotherapies, and we believe NorthStar can be a key catalyst of this change. As we enter this next stage of our evolution and growth, the opportunities are enormous and having strong board members with a wealth of diverse, deep industry experience will help us unlock the promise our business holds for our industry, doctors, and their patients. I look forward to Pete joining the NorthStar Board."

    About NorthStar Medical Technologies, LLC (NorthStar)

    NorthStar Medical Technologies, based in Beloit, Wis., is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC. NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar's comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240415270559/en/

    Get the next $FREQ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FREQ
    $URGN
    $VYGR
    $IMMU

    CompanyDatePrice TargetRatingAnalyst
    UroGen Pharma Ltd.
    $URGN
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    UroGen Pharma Ltd.
    $URGN
    5/22/2025Buy → Neutral
    H.C. Wainwright
    UroGen Pharma Ltd.
    $URGN
    4/16/2025$23.00Sector Outperform
    Scotiabank
    UroGen Pharma Ltd.
    $URGN
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    Voyager Therapeutics Inc.
    $VYGR
    1/10/2025Overweight
    Cantor Fitzgerald
    Voyager Therapeutics Inc.
    $VYGR
    12/2/2024$12.00Buy
    Citigroup
    Voyager Therapeutics Inc.
    $VYGR
    11/29/2024$7.00 → $11.00Outperform
    Wedbush
    Voyager Therapeutics Inc.
    $VYGR
    10/16/2024$15.00Outperform
    Leerink Partners
    More analyst ratings

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UroGen Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded UroGen Pharma from Neutral to Buy and set a new price target of $50.00

      6/16/25 7:44:13 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma downgraded by H.C. Wainwright

      H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral

      5/22/25 8:22:21 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on UroGen Pharma with a new price target

      Scotiabank initiated coverage of UroGen Pharma with a rating of Sector Outperform and set a new price target of $23.00

      4/16/25 8:14:26 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-58) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 11/22/2024. Application Category: BLA, Application Number: 761115, Application Classification:

      11/25/24 4:48:58 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-35) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 02/03/2023. Application Category: BLA, Application Number: 761115, Application Classification:

      2/3/23 11:40:04 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • FDA Approval for TRODELVY issued to IMMUNOMEDICS INC

      Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-23) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/03/2022. Application Category: BLA, Application Number: 761115, Application Classification:

      6/6/22 4:34:38 AM ET
      $IMMU
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    SEC Filings

    See more
    • SEC Form 8-K filed by UroGen Pharma Ltd.

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      7/3/25 4:16:10 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by UroGen Pharma Ltd.

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      6/13/25 8:00:29 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by UroGen Pharma Ltd.

      SCHEDULE 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      6/9/25 7:19:46 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

      PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The UTOPIA trial enrolled 99 patients across multiple centers globally. UGN-103 uses UroGen's proprietary sustained release RTGel® technology, a reverse-thermal hydrogel that enables sus

      7/7/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

      ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech com

      6/12/25 1:28:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

      LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Compan

      6/10/25 7:00:51 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $38,044 worth of Ordinary Shares (5,162 units at $7.37), increasing direct ownership by 3% to 153,378 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      6/11/25 9:14:14 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vitale Nancy

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      6/4/25 9:09:17 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Scangos George A

      4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

      6/4/25 9:08:12 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Leadership Updates

    Live Leadership Updates

    See more
    • UroGen Appoints Chris Degnan as Chief Financial Officer

      Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

      10/9/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

      LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe

      6/13/24 7:00:00 AM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UroGen Pharma Appoints David Lin as New Chief Commercial Officer

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

      6/3/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Financials

    Live finance-specific insights

    See more
    • U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

      ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech com

      6/12/25 1:28:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

      New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July Oncologic Drugs Advisory Committee scheduled for May 21, 2025 JELMYTO® achieved net product sales of $20.3 million in Q1 2025, compared with $18.8 million in Q1 2024, driven by underlying demand growth of 12% $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2025 Conference call and webcast to be held today at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and sp

      5/12/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      Conference Call and Webcast Scheduled for Monday, May 12, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroG

      5/1/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FREQ
    $URGN
    $VYGR
    $IMMU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

      SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/18/24 6:16:04 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 7:46:37 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 6:13:11 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care